MENU
+Compare
EXEL
Stock ticker: NASDAQ
AS OF
Aug 15 closing price
Price
$38.31
Change
-$0.20 (-0.52%)
Capitalization
10.31B

EXEL Exelixis Forecast, Technical & Fundamental Analysis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer... Show more

Industry: #Biotechnology
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for EXEL with price predictions
Aug 15, 2025

EXEL in -0.47% downward trend, declining for three consecutive days on August 15, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where EXEL declined for three days, in of 260 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

EXEL moved below its 50-day moving average on July 29, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EXEL crossed bearishly below the 50-day moving average on July 30, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The Aroon Indicator for EXEL entered a downward trend on August 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EXEL's RSI Indicator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 12, 2025. You may want to consider a long position or call options on EXEL as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EXEL just turned positive on August 15, 2025. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .

EXEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EXEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.071) is normal, around the industry mean (19.407). P/E Ratio (18.418) is within average values for comparable stocks, (50.758). Projected Growth (PEG Ratio) (2.598) is also within normal values, averaging (2.852). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (4.973) is also within normal values, averaging (299.803).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

EXEL is expected to report earnings to fall 9.05% to 68 cents per share on November 04

Exelixis EXEL Stock Earnings Reports
Q3'25
Est.
$0.68
Q2'25
Beat
by $0.11
Q1'25
Beat
by $0.25
Q4'24
Beat
by $0.16
Q3'24
Beat
by $0.13
The last earnings report on July 28 showed earnings per share of 75 cents, beating the estimate of 63 cents. With 2.37M shares outstanding, the current market capitalization sits at 10.31B.
A.I. Advisor
published General Information

General Information

a developer of small molecule therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1851 Harbor Bay Parkway
Phone
+1 650 837-7000
Employees
1310
Web
https://www.exelixis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ICLN14.100.44
+3.22%
iShares Global Clean Energy ETF
DBEZ52.650.01
+0.02%
Xtrackers MSCI Eurozone Hedged Eq ETF
PFFV23.10N/A
N/A
Global X Variable Rate Preferred ETF
EQIN45.42N/A
N/A
Columbia US Equity Income ETF
WEED19.79-2.05
-9.39%
Roundhill Cannabis ETF

EXEL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with JAZZ. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then JAZZ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
-0.42%
JAZZ - EXEL
35%
Loosely correlated
+0.94%
RIGL - EXEL
29%
Poorly correlated
+4.28%
RVMD - EXEL
28%
Poorly correlated
+0.83%
ADCT - EXEL
28%
Poorly correlated
-1.88%
ACLX - EXEL
28%
Poorly correlated
+3.09%
More